



Herma Heart Institute



Froedtert

&

MEDICAL  
COLLEGE of  
WISCONSIN


# UPDATE: Risk Stratification and Management of Hereditary Thoracic Aortic Aneurysms

**Salil Ginde, MD, MPH**

Director, Marfan and Related Connective Tissue Disorder Program

Children's Wisconsin and Froedtert Hospital

Medical College of Wisconsin



# Objectives

- Discuss new insights into the genetic basis of hereditary thoracic aortic disease
- Utilizing both genetic testing and imaging to guide medical and surgical management

# Disclosures Dr. Salil Ginde

I have no relevant financial disclosures

# Aortic Aneurysms



**Aortic dissection**



Thoracic aortic aneurysm prevalence = 1%

Type A Dissection

- 50% mortality before hospital admission
- 1-2% of all deaths in Western countries

# Causes of Aortic Aneurysms

- Hypertension and/or atherosclerosis
- Inflammatory conditions
- Traumatic injury
- Genetic conditions (inherited disorder of connective tissue)  
     $\approx$  20-25% of cases

# Characterizing the Young Patient With Aortic Dissection: Results From the International Registry of Aortic Dissection (IRAD)

**Table 1.** Baseline Demographics of Patients in the International Registry of Aortic Dissection Based on Age Categories of <40 and ≥40 Years of Age

Variables	Age <40 n = 68 (%)	Age ≥40 n = 883 (%)	p Value
Age, yrs (mean ± SD)	30.7 ± 6.6	63.9 ± 11.5	NA
Type of dissection			NS
Type A	46 (68)	574 (65)	
Type B	22 (32)	309 (35)	
Male gender	52 (76)	596 (67)	NS
White race	55 (81)	699 (79)	NS
Diabetes	0 (0)	38 (4)	NS
Hypertension	23 (34)	635 (72)	<0.001
Atherosclerosis	1 (1)	267 (30)	<0.001
Marfan syndrome	34 (50)	19 (2)	<0.001
Prior aortic valve disease	7 (10)	74 (8)	NS
Bicuspid aortic valve (n = 516)	6 (9)	12 (1)	<0.001
Known aortic aneurysm	13 (19)	115 (13)	NS
Prior aortic dissection	5 (7)	50 (6)	NS

en's  
sin



Herma Heart Institute

# Conditions Predisposing to Thoracic Aneurysms

- Syndromic Disorders (several non-cardiac features)
  - Marfan Syndrome
  - Loeys-Dietz Syndrome
  - Vascular Ehlers-Danlos Syndrome
  - Autosomal Dominant Polycystic Kidney Disease
  - Turner Syndrome
- Non-syndromic Disorders (near-normal phenotype)
  - Bicuspid aortic valve
  - Familial Thoracic Aortic Aneurysm/Dissection
  - Variants of Loeys-Dietz Syndrome

## Extracellular Matrix

## TGF $\beta$ signaling






Figure 2 | **Signalling pathways involved in familial thoracic aortic aneurysms (TAA).** The proteins encoded by genes in which mutations cause familial TAA are indicated with a green asterisk. **a** | Mechanical stimuli activate

# Marfan Syndrome


- Autosomal dominant mutation in gene coding for fibrillin -1 (FBN1)
- Three organ systems are the most affected:
  - Musculoskeletal system (pectus, scoliosis)
  - Eye (lens dislocation)
  - Aneurysms/Dissection, Mitral valve prolapse

\* High degree of clinical variability




# MARFAN SYNDROME

- Autosomal dominant mutation in gene coding for fibrillin 1 (FBN-1)
- Extracellular matrix protein
  - ◆ Major component of microfibrils associated with elastin fibers
  - ◆ Elastin fibers
    - ◆ Function in mediating elastic recoil of tissues



# Structural role of Fibrillin-1



# Marfan Syndrome - Outcomes



**Aortic dissection**

- Aortic complications (dissection, rupture) most common causes of death
- Average life expectancy
  - In 1972 – 45 years<sup>1</sup>
  - In 1995 – 72 years (similar to general population)<sup>2</sup>

<sup>1</sup>Murdoch et al. N Engl J Med 1972

<sup>2</sup>Silverman et al. Am J Cardiol 1995

# Management of Aortic Aneurysms

## Goals

1. Slow the growth of the aneurysm overtime
  - a) Medications
  - b) Restrictions to vigorous physical activity
2. Preventative surgery before aortic dissection

# PROGRESSION OF AORTIC DILATATION AND THE BENEFIT OF LONG-TERM $\beta$ -ADRENERGIC BLOCKADE IN MARFAN'S SYNDROME

JENNIFER SHORES, M.D., KENNETH R. BERGER, M.D., PH.D., EDMOND A. MURPHY, M.D., SC.D.,  
AND REED E. PYERITZ, M.D., PH.D.


---

- 1994
- 70 teen and adult pts with Marfan syndrome
  - 32 given propranolol
  - 38 given placebo
- Followed for up to 10 years


# PROGRESSION OF AORTIC DILATATION AND THE BENEFIT OF LONG-TERM $\beta$ -ADRENERGIC BLOCKADE IN MARFAN'S SYNDROME

JENNIFER SHORES, M.D., KENNETH R. BERGER, M.D., PH.D., EDMOND A. MURPHY, M.D., SC.D.,  
AND REED E. PYERITZ, M.D., PH.D.

## Slowed rate of aortic dilation



## Lowered risk for aortic complications




# Beta-blockers and Marfan Syndrome

- Beta blockers became primary medication to slow growth of aortic aneurysms
- Subsequent studies showed that majority of patients on beta-blockers
  1. still had progression of aneurysm
  2. at risk for aortic dissection and/or needed heart surgery.

# Marfan Mouse Model



- 2003
- Harry Dietz, MD
- Created FBN1+/- Marfan syndrome mouse model (FBN1+/-)
- Fibrillin has more than a structural role



# Functional role of Fibrillin-1


Mouse model showed that:

- Fibrillin-1 regulates a growth factor - TGF-B
- Mice had  $\uparrow\uparrow$  TGF-B


## Regulates cellular function

Cell proliferation  
Cell cycle arrest  
Cell apoptosis  
Cell differentiation  
Extracellular formation

**Losartan**



# Losartan in Marfan Mouse





# Marfan syndrome

Fibrillin gene mutation

Losartan

Beta blockers

## LORSARTAN vs. BETA-BLOCKERS



Aortic Aneurysm

# *The* NEW ENGLAND JOURNAL *of* MEDICINE

ESTABLISHED IN 1812


NOVEMBER 27, 2014


VOL. 371 NO. 22

## Atenolol versus Losartan in Children and Young Adults with Marfan's Syndrome

- 21 centers through Pediatric Heart Network
- 608 Marfan syndrome patients (6 months to 25 years old)
  - 303 received atenolol
  - 305 received losartan
- Followed with echocardiograms for 3 years

A





# Recommendations for Medical Management

- After Marfan syndrome diagnosed, start either beta-blocker or ARB (losartan or irbesartan)
- Monitor with echocardiogram +/- CT or MRI at least every year
- If aneurysm grows on single therapy, then add a second medication

## Extracellular Matrix

## TGFβ signaling




Figure 2 | **Signalling pathways involved in familial thoracic aortic aneurysms (TAA).** The proteins encoded by genes in which mutations cause familial TAA are indicated with a green asterisk. **a** | Mechanical stimuli activate



# Loeys Dietz Syndrome – Discriminating Features


## HEAD AND NECK:

Head	Craniosynostosis
Eye	<u>No lens dislocation</u>
Face	<b>Malar hypoplasia</b> / Micrognathia / Retrognathia
Eyes	<b>Hypertelorism</b> / Exotropia / Blue sclerae / Proptosis
Mouth	<u>Bifid uvula</u> / <u>Cleft palate (uncommon)</u>



## CARDIOVASCULAR:

**Aortic dissection at smaller dimensions (>4.5 cm)**  
Arterial tortuosity, generalized  
**Cerebral aneurysm**



## SKELETAL: **Joint laxity**

FEET            **Talipes equinovarus (club foot)**

SKIN            **Velvety texture** / Translucent skin



## NEUROLOGIC:

Chiari malformation  
 Hydrocephalus  
 DD/MR

# **2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease**

**A Report of the American College of Cardiology Foundation/American Heart Association  
Task Force on Practice Guidelines, American Association for Thoracic Surgery, American  
College of Radiology, American Stroke Association, Society of Cardiovascular  
Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of  
Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine**

## **Criteria for Prophylactic Aortic Root Replacement:**

- Marfan syndrome = 5.0 cm
- Loeys-Dietz syndrome = 4.5 cm


# Loeys-Dietz Syndrome

Genetic Variant	Aortic Event	Age at Aortic Event	Aneurysm Repair/Dissect	Type A/Type B Dissection	Aortic size at time of Dissection
TGFBR1	39%	28 yrs (12-72)	50%/50%	91%/9%	58.3 mm
TGFBR2	44%	35 yrs (8-85)	54%/46%	69%/31%	51.4 mm
SMAD3	37%	47 yrs (25-77)	30%/70%	76%/13%	54 mm
TGFB2	21%	35 yrs (31-60)	50%/50%	N/A	52 mm


Jondeau, et al. Circ Cardiovasc Genet 2016  
 Hostetler, et al. J Med Genet 2019  
 Boileau, et al. Nat Genet 2021

# Gender Differences in Age of Aortic Events

## TGFBR1 mutation



## TGFBR2 mutation



# Loeys-Dietz Syndrome: Dissections < 4.5 cm

- TGFBR 1 and 2 (6 patients)
  - Female
  - Aortic tortuosity
  - Hypertelorism
  - Wide scars
- SMAD3 (3 patients)
  - HTN
  - History of smoking

Jondeau, et al. Circ Cardiovasc Genet 2016  
Hostetler, et al. J Med Genet 2019

## Extracellular Matrix

## TGF $\beta$ signaling







Figure 2 | **Signalling pathways involved in familial thoracic aortic aneurysms (TAA).** The proteins encoded by genes in which mutations cause familial TAA are indicated with a green asterisk. **a** | Mechanical stimuli activate

# Nonsyndromic Hereditary Thoracic Aortic Disease



- Autosomal dominant inheritance
- Decreased penetrance, variable expression
- Minimal systemic features
- 20% of pts have a first-degree relative w/ TAAD
- Caused by genetic variants that disrupt a protein in SMC contractile unit and alter smooth muscle cell force generation



# Smooth Muscle Cell Contraction





# ACTA2-Associated Aortic Disease




Median Age at Aortic Event = 36 y/o  
33% Dissected at Dimension < 5.0 cm

# ACTA2-Associated Aortic Disease




# ACTA2-Associated Aortic Disease



## R149 and R118


- Predispose to early onset coronary artery disease

# Smooth Muscle Cell Contraction





# MYLK-Associated Aortic Events

## Overall Risk




## Missense vs. Null Variants








# Gene-based Timing of Prophylactic ARR




# Aortic Root Replacement

Composite Mechanical  
Valve

Valve Sparing



# HHI/MCW Valve-sparing ARR Outcomes



# HHI/MCW Aortopathy Clinic

## Indications for Referral

- Systemic features of connective tissue disorder (i.e. pectus, scoliosis, wrist/thumb sign, cleft palate, club feet, etc.)
- Family history of thoracic aneurysms or dissections
- Aortic dissection < 60 years of age
- Ascending aortic aneurysm diagnosed < 50-60 years of age

# HHI/MCW Aortopathy Clinic

1. Patient/family evaluated by Cardiology & Genetics (Med-Peds providers)
  2. Custom HTAD gene panel (> 20 genes)
- If positive genetic testing ( $\approx$  20-30%) → Gene-specific management
    - Medical therapy (beta-blocker or ARB), activity restrictions
    - Surveillance imaging (+/- head/neck imaging)
    - Timing of aortic aneurysm repair
  - If negative testing or variant of unknown significance ( $\approx$  70-80%)
    - Imaging of first-degree relatives
    - Whole Exome Sequencing

# Summary

- Evolving understanding of how genetic variants result in hereditary thoracic aortic disease
- Identifying causative HTAD genetic variant critical for:
  - Screening for aortic and vascular complications
  - Guide medical and surgical management
  - Identifying at-risk family members

Thank You



Salil Ginde, MD  
Phone: 414-266-4757  
Email: [sginde@mcw.edu](mailto:sginde@mcw.edu)



Herma Heart Institute

